A Financial Model for Team-Based Opioid Use Disorder Treatment

References

1. 1.↵
   Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2019. Available from: https://www.samhsa.gov/data/.
2. 2.↵
   National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press; 2019.
3. 3.↵
   The Council of Economic Advisors. The underestimated costs of the opioid crisis. November 2017. Available from: https://www.whitehouse.gov/sites/whitehouse.gov/files/images/The%20Underestimated%20Cost% 20of%20the%20Opioid%20Crisis.pdf. Accessed May 17, 2019.
4. 4.↵
   Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63, Full Document. HHS Publication No. (SMA) 18-5063FULLDOC. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
5. 5.↵
   1. Kampman K,
   2. Jarvis M

   . The ASAM National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use, J Addict Med 2015;9:358–67.

   OpenUrlCrossRefPubMed
6. 6.↵
   National Institute on Drug Abuse. Medications to Treat Opioid Use Disorder. Rockville, MD: National Institute on Drug Abuse, 2018.
7. 7.↵
   Substance Abuse and Mental Health Services Administration. Practitioner and Program Data. Available from: https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/practitioner-program-data. Accessed September 10, 2019.
8. 8.↵
   1. Moran GE,
   2. Snyder CM,
   3. Noftsinger RF,
   4. et al

   . Implementing medication-assisted treatment for opioid use disorder in rural primary care: environmental scan, volume 1. Rockville, MD: Agency for Healthcare Research and Quality; October 2017.
9. 9.↵
   1. Deflavio JR,
   2. Rolin SA,
   3. Nordstrom BR,
   4. Kazal LA

   . Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural and Remote Health 2015;15:3019.

   OpenUrl
10. 10.↵
    1. Alford DP,
    2. LaBelle CT,
    3. Kretsch N,
    4. et al

    . Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med 2011;171:425–31.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Andrilla CH,
    2. Coulthard C,
    3. Larson E

    . Barriers rural physicians face prescribing buprenorphine for opioid use disorder. Ann Fam Med 2017;15:359–62.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Wilson CG,
    2. Fagan EB

    . Providing office-based treatment of opioid use disorder. Ann Fam Med 2017;15:481.

    OpenUrlFREE Full Text
13. 13.↵
    North Carolina Department of Health and Human Services. Annual Visit. Available from: https://medicaid.ncdhhs.gov/providers/programs-services/annual-visit. Accessed September 12, 2019.
14. 14.↵
    North Carolina Department of Health and Human Services. Physician fee schedule. Available from: https://files.nc.gov/ncdma/documents/Fee-Schedules/Physician-Services-Fee-Schedule20190607.pdf. Accessed June 13, 2019.
15. 15.↵
    Centers for Medicare and Medicaid Services. Physician fee schedule. Available from: www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx. Accessed September 26, 2019.
16. 16.↵
    2019 MGMA DataDive Provider Compensation, based on 2018 data. 2019. Used with permission from MGMA, 104 Inverness Terrace East, Englewood, Colorado 80112. 877.275.6462. Available from: www.mgma.com.
17. 17.↵
    American Medical Association Opioid Task Force. 2019 Progress Report. Available from: https://www.ama-assn.org/system/files/2019-06/opioid-task-force-progress-report.pdf. Accessed June 13, 2019.
18. 18.↵
    1. Chou R,
    2. et al

    . Medication-assisted treatment models of care for opioid use disorder in primary care settings. Rockville, MD: Agency for Healthcare Research and Quality; 2016.
19. 19.↵
    1. Korthuis PT,
    2. McCarty D,
    3. Weimer M,
    4. et al

    . Primary care-based models for the treatment of opioid use disorder. Ann Intern Med 2017;166:268–279.

    OpenUrl
20. 20.↵
    1. DiPaula BA,
    2. Menachery E

    . Physician-pharmacist collaborative care model for buprenorphine-maintained- opioid-dependent patients. J Amer Pharm Assoc 2015;55:187–92.

    OpenUrl
21. 21.↵
    Medicare Shared Savings Program. Quality measure benchmarks for the 2018 and 2019 reporting years. Guidance document. February 2019. Version #2. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/2018-and-2019-quality-benchmarks-guidance.pdf. Accessed June 13, 2019.
22. 22.↵
    National Committee for Quality Assurance. HEDIS Measures. Washington, DC: National Committee for Quality Improvement; 2019.
23. 23.↵
    National Qualified Forum. National qualified forum measures 2019. Available from: www.qualityforum.org. Accessed April 30, 2019.
24. 24.↵
    Centers for Disease Control and Prevention. Quality improvement and care coordination: implementing the CDC guideline for prescribing opioids for chronic pain. Available from: https://www.cdc.gov/drugoverdose/pdf/prescribing/CDC-DUIP-QualityImprovementAndCareCoordination-508.pdf. Accessed June 13, 2019.